179 related articles for article (PubMed ID: 15300803)
1. Use of adenoviruses encoding CD40L or IL-2 against B cell lymphoma.
Meziane el K; Bhattacharyya T; Armstrong AC; Qian C; Hawkins RE; Stern PL; Dermime S
Int J Cancer; 2004 Oct; 111(6):910-20. PubMed ID: 15300803
[TBL] [Abstract][Full Text] [Related]
2. CpG oligodeoxynucleotides enhance the capacity of adenovirus-mediated CD154 gene transfer to generate effective B-cell lymphoma vaccines.
Rieger R; Kipps TJ
Cancer Res; 2003 Jul; 63(14):4128-35. PubMed ID: 12874017
[TBL] [Abstract][Full Text] [Related]
3. In vivo antitumor effect of CD40L-transduced tumor cells as a vaccine for B-cell lymphoma.
Briones J; Timmerman J; Levy R
Cancer Res; 2002 Jun; 62(11):3195-9. PubMed ID: 12036933
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
5. Antitumor immunity after vaccination with B lymphoma cells overexpressing a triad of costimulatory molecules.
Briones J; Timmerman JM; Panicalli DL; Levy R
J Natl Cancer Inst; 2003 Apr; 95(7):548-55. PubMed ID: 12671023
[TBL] [Abstract][Full Text] [Related]
6. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma.
Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK
Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458
[TBL] [Abstract][Full Text] [Related]
7. Dendritic and tumor cell fusions transduced with adenovirus encoding CD40L eradicate B-cell lymphoma and induce a Th17-type response.
Alvarez E; Moga E; Barquinero J; Sierra J; Briones J
Gene Ther; 2010 Apr; 17(4):469-77. PubMed ID: 20010627
[TBL] [Abstract][Full Text] [Related]
8. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
Guinn BA; DeBenedette MA; Watts TH; Berinstein NL
J Immunol; 1999 Apr; 162(8):5003-10. PubMed ID: 10202049
[TBL] [Abstract][Full Text] [Related]
9. B7-2 expression above a threshold elicits anti-tumor immunity as effective as interleukin-12 and prolongs survival in murine B-cell lymphoma.
Pizzoferrato E
Int J Cancer; 2004 May; 110(1):61-9. PubMed ID: 15054869
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic vaccination against murine lymphoma by intratumoral injection of recombinant fowlpox virus encoding CD40 ligand.
Liu A; Guardino A; Chinsangaram L; Goldstein MJ; Panicali D; Levy R
Cancer Res; 2007 Jul; 67(14):7037-44. PubMed ID: 17638917
[TBL] [Abstract][Full Text] [Related]
11. Improved immunogenicity of a self tumor antigen by covalent linkage to CD40 ligand.
Huang HI; Wu PY; Teo CY; Chen MN; Chen YC; Silin D; Tao MH
Int J Cancer; 2004 Feb; 108(5):696-703. PubMed ID: 14696096
[TBL] [Abstract][Full Text] [Related]
12. CD40ligand-expressing dendritic cells induce regression of hepatocellular carcinoma by activating innate and acquired immunity in vivo.
Gonzalez-Carmona MA; Lukacs-Kornek V; Timmerman A; Shabani S; Kornek M; Vogt A; Yildiz Y; Sievers E; Schmidt-Wolf IG; Caselmann WH; Sauerbruch T; Schmitz V
Hepatology; 2008 Jul; 48(1):157-68. PubMed ID: 18537185
[TBL] [Abstract][Full Text] [Related]
13. Herpes simplex virus (HSV) amplicon-mediated codelivery of secondary lymphoid tissue chemokine and CD40L results in augmented antitumor activity.
Tolba KA; Bowers WJ; Muller J; Housekneckt V; Giuliano RE; Federoff HJ; Rosenblatt JD
Cancer Res; 2002 Nov; 62(22):6545-51. PubMed ID: 12438249
[TBL] [Abstract][Full Text] [Related]
14. A hexon and fiber-modified adenovirus expressing CD40L improves the antigen presentation capacity of dendritic cells.
Liljenfeldt L; Yu D; Chen L; Essand M; Mangsbo SM
J Immunother; 2014 Apr; 37(3):155-62. PubMed ID: 24598450
[TBL] [Abstract][Full Text] [Related]
15. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
Guinn BA; Bertram EM; DeBenedette MA; Berinstein NL; Watts TH
Cell Immunol; 2001 May; 210(1):56-65. PubMed ID: 11485353
[TBL] [Abstract][Full Text] [Related]
16. Modulation of cellular responses by plasmid CD40L: CD40L plasmid vectors enhance antigen-specific helper T cell type 1 CD4+ T cell-mediated protective immunity against herpes simplex virus type 2 in vivo.
Sin JI; Kim JJ; Zhang D; Weiner DB
Hum Gene Ther; 2001 Jun; 12(9):1091-102. PubMed ID: 11399230
[TBL] [Abstract][Full Text] [Related]
17. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
18. Autologous antileukemic immune response induced by chronic lymphocytic leukemia B cells expressing the CD40 ligand and interleukin 2 transgenes.
Takahashi S; Rousseau RF; Yotnda P; Mei Z; Dotti G; Rill D; Hurwitz R; Marini F; Andreeff M; Brenner MK
Hum Gene Ther; 2001 Apr; 12(6):659-70. PubMed ID: 11426465
[TBL] [Abstract][Full Text] [Related]
19. Vaccination with immature dendritic cells combined with CD40mAb induces protective immunity against B lymphoma in hu-SCID mice.
Ge Y; Xi H; Zhang XG
Biomed Pharmacother; 2010 Sep; 64(7):487-92. PubMed ID: 20382498
[TBL] [Abstract][Full Text] [Related]
20. An injectable synthetic immune-priming center mediates efficient T-cell class switching and T-helper 1 response against B cell lymphoma.
Singh A; Qin H; Fernandez I; Wei J; Lin J; Kwak LW; Roy K
J Control Release; 2011 Oct; 155(2):184-92. PubMed ID: 21708196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
